Reoviruses as Cancer Therapeutics
This white paper by Matt Coffey, Ph.D., chief scientific officer, Oncolytics Biotech, discusses a new virus product, Reolysin, that aims to attack cancer cell types with only mild side effects in comparison to traditional cytotoxic cancer therapies which cause serious health risks.
| Published: | 2008 |
| Format: | |
| Length: | 5 pages |
| Type: | White paper |
| Language: | English |
.
SPONSORED REPORTS
